CD8A and inflammatory breast carcinoma: Our study demonstrates for the first time that LMP7 inhibition has potential therapeutic value in LMP7-expressing TNBC/IBC because it directly perturbs cancer cell viability and reshapes the TME, particularly via the activation of CD8+ T cells and the suppression of M2 macrophages.